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Matrix metalloproteases are key regulatory molecules in the breakdown of extracellular matrix and in inflammatory
processes. Matrix metalloproteinase-1 (MMP-1) can significantly enhance muscle regeneration by promoting
the formation of myofibers and degenerating the fibrous tissue. Herein, we prepared novel MMP-1-loaded poly
(lactide-co-glycolide-co-caprolactone) (PLGA-PCL) nanoparticles (NPs) capable of sustained release of MMP-1.
We established quadratic equations as mathematical models and employed rotatable central composite design and
response surface methodology to optimize the preparation procedure of the NPs. Then, characterization of the
optimized NPs with respect to particle size distribution, particle morphology, drug encapsulation efficiency, MMP-1
activity assay and in vitro release of MMP-1 from NPs was carried out. The results of mathematical modeling show
that the optimal conditions for the preparation of MMP-1-loaded NPs were as follows: 7 min for the duration time
of homogenization, 4.5 krpm for the agitation speed of homogenization and 0.4 for the volume ratio of organic
solvent phase to external aqueous phase. The entrapment efficiency and the average particle size of the NPs were
38.75 ± 4.74% and 322.7 ± 18.1 nm, respectively. Further scanning electron microscopy image shows that the NPs
have a smooth and spherical surface, with mean particle size around 300 nm. The MMP-1 activity assay and in vitro
drug release profile of NPs indicated that the bioactivity of the enzyme can be reserved where the encapsulation
allows prolonged release of MMP-1 over 60 days. Taken together, we reported here novel PLGA-PCL NPs for
sustained release of MMP-1, which may provide an ideal MMP-1 delivery approach for tissue reconstruction therapy.
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Matrix metalloproteinases (MMPs) are a family of
enzymes capable of degrading extracellular matrix proteins
[1]. This ability is a requirement for cell migration and* Correspondence: songhua@sjtu.edu.cn; ghongquan@hotmail.com
1Department of Pediatric Urology, Xinhua Hospital, Shanghai Jiao Tong
University School of Medicine, 1665 KongJiang Road, Shanghai 200092,
People's Republic of China
2Department of Bio-Nano Science and Engineering, Key Laboratory for Thin
Film and Microfabrication of Ministry of Education, Institute of Micro-Nano
Science and Technology, Shanghai Jiao Tong University, 800 Dongchuan
Road, Shanghai 200240, People's Republic of China
Full list of author information is available at the end of the article
© 2012 Sun et al.; licensee Springer. This is an
Attribution License (http://creativecommons.or
in any medium, provided the original work is ptissue remodeling, both of which play essential roles in
embryonic development, reproduction, tissue remodeling
as well as many other physiological and pathological pro-
cesses. Matrix metalloproteinase-1 (MMP-1), known as
interstitial collagenase, plays a pivotal role in degrading
collagen and resolving scar to enhance muscle healing [2-
4]. Several investigations have shown that direct injection
of proMMP-1 into fibrotic skeletal muscle resulted in the
reduction of collagen content without adversely affecting
the uninjured muscle. More recently, a poly(ethylene gly-
col) (PEG)-modified form of MMP-1 (PEG-MMP-1) has
also been reported, which was prepared by reactingOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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bility of enzymes and better efficacy in degrading interfi-
brillar collagen. However, modification with PEG resulted
in the inactivation of MMP-1 towards collagen and did
not enhance the stability of the enzyme [5]; therefore, su-
perior formulations are still needed to deliver MMP-1
continuously to maintain the drug concentration and
effectiveness for long-term tissue reconstruction therapy.
So far, a number of artificial polymers have been investi-
gated extensively to formulate the biodegradable nano-drug
delivery carriers, such as polylactide, poly-L-lactic acid
(PLLA), polycaprolactone (PCL) and poly(lactide-co-glyco-
lide) (PLGA) [6,7]. Even though they are biocompatible and
biodegradable polymers approved by FDA as safe biomater-
ials for clinical application, the application of polymer
nanoparticles (NPs) is still limited because of polymer
crystallization, poor flexible property or low biodegradation
rate. For example, because of PLLA's high crystallization
and relatively low biodegradation rate, the drug release
from the PLLA drug carriers is mainly controlled by drug
diffusion, a similar way to the nondegradable drug carriers
[8,9]. Recently, poly(lactide-co-glycolide-co-caprolactone)
(PLGA-PCL), a novel biodegradable block copolymer,
has attracted much attention because it colligates the
advantages of PLGA and PCL. Characteristics such as
excellent biocompatibility, suitable degradable rate, low
glass transition temperature (Tg), good miscibility and
great permeability make PLGA-PCL an ideal candidate
for sustained drug release delivery systems [10].
In general, the preparation of the NPs is a complicated
process where a wide variety of different variables may
affect the properties of the final products, including par-
ticle size distribution, particle morphology, drug encap-
sulation efficiency and so on. It is a big challenge to
experimentally determine how the properties of the NPs
are influenced by potential interactions between prepar-
ation factors. In this study, we prepared novel MMP-1-
loaded PLGA-PCL NPs using double emulsion and
solvent evaporation technique. Rotatable central com-
posite design (RCCD) and response surface methodology
(RSM) were used to investigate and optimize the impact
of critical factors, namely duration of homogenization, agi-
tation speed and volume ratio of organic solvent phase to
external aqueous phase, on the response properties of the
yielded NPs, such as mean particle size and entrapment
efficiency [11,12]. We first incorporated these multiple fac-
tors into mathematical polynomial equation models; sec-
ond, we solved the equations and analyzed the response
surface contour and plots, and lastly, the computational de-
sign of the preparation conditions enabled us to achieve
the optimized NPs. Additionally, characterization and char-
acteristics of the optimized MMP-1-loaded NPs including
particle size distribution, particle morphology, drug en-
capsulation efficiency, activity assay of encapsulatedMMP-1 as well as in vitro drug release behavior were car-
ried out. We believe that the optimized novel NPs would
be an ideal MMP-1 prolonged release delivery system.
Methods
Materials
MMP-1, TweenW 80 (polyoxyethylene sorbitan monoole-
ate), poly(vinyl alcohol) (PVA; MW 14–16 kDa), PluronicW
F127 triblock copolymer and p-aminophenylmercuric
(APMA) were purchased from Sigma-Aldrich (Shanghai,
China). The thioester substrate Acetyl-Pro-Leu-Gly-[2-
mercapto-4-methyl-pentanoyl]-Leu-Gly-OC2H5 was from
Biomol International L.P. (Plymouth Meeting, PA, USA).
Poly(L-lactide-co-glycolide-co-caprolactone) (L-lactide/glycolide/
caprolactone 70:10:20 molar ratio, inherent viscosity
1.30 dl/g, in chloroform) was obtained from Daigang
Biomaterial Co., Ltd. (Jinan, China). MMP-1 enzyme-linked
immunosorbent assay (ELISA) kit was from Fengxiang
Biotech Co., Ltd. (Shanghai, China). All other reagents
were purchased from Sigma-Aldrich.
Preparation of MMP-1-loaded NPs
PLGA-PCL NPs containing MMP-1 (0.1 μg/mg of NPs)
were prepared by double emulsion-solvent evaporation
technique based on the method of Liao et al. with modi-
fications [13,14]. Briefly, 20 mg of PLGA-PCL was dis-
solved in an appropriate amount of dichloromethane
and poured into 100 μL of phosphate buffer saline (PBS;
pH 7.4) as the inner aqueous phase (W1) containing
MMP-1. Then, the inner emulsion (W1/O) was gener-
ated by a high-speed IKA Ultra Turrax homogenizer
(IKA, Guangzhou, China) operating at 3,000 rpm for
2 min. Next, the inner emulsion was injected into 10 mL of
outer aqueous phase (W2), which was composed of aque-
ous 1.5% PVA (w/v) and 2% Tween 80. Multiple emulsion
(W1/O/W2) was achieved by homogenization with a high-
speed homogenizer at selected speed and time following
incubation on ice, and then putting on a rota-evaporator
under vacuum (500 mHg) for 3 h at room temperature for
the complete evaporation of organic solvent, which led the
precipitation of copolymer to form solid NPs. Then, the
NPs were collected by centrifugation at 10,000× g for
5 min and washed with distilled water three times, followed
by freeze-drying using mannitol as cryoprotectant (PLGA-
PCL/mannitol 100:30) to get dry powder containing NPs.
Experimental design
In recent years, RCCD-RSM, a combined analysis tech-
nique of mathematics and statistics, has been widely
used to evaluate the effects of multiple variables and to
optimize complicated chemical and biotechnological
processes. RCCD enables several independent variables
to be investigated at the same time using a relatively small
number of experiments. RSM optimization method can
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RSM can define the interactions between factors, avoid
unnecessary experiments and obtain optimized results.
Our pilot experiments suggested that the independent
variables such as duration time of homogenization, agita-
tion speed of homogenization and volume ratio of organic
solvent phase to external aqueous phase were the main
factors that affected the particle size distribution and
encapsulation efficiency of the NPs. For each independent
variable, we took into consideration the feasibility of pre-
paring NPs at extreme values and selected the experimen-
tal range and the factor levels based on the results of our
pilot experiments, which are listed in Table 1. A total of
20 tests are presented in Table 2. All the formulations in
these experiments were prepared in triplicate.
Characterization of MMP-1-loaded NPs
Particle size
The mean diameter of the NPs was measured by dyn-
amic light scattering (DLS) analysis using a NICOMP
380 ZLS zeta potential/particle sizer (PSS Nicomp, Santa
Barbara, CA, USA) equipped with a 5-mW helium-neon
laser at a wavelength of 633 nm and 90° scattering angle.
All samples were diluted with ddH2O to produce a
suitable scattering intensity before measurement. Each
analysis was repeated three times.
Surface morphology
The morphological examination of the NPs was per-
formed by scanning electron microscopy (SEM; Carl Zeiss
SMT, Oberkochen, Germany) [15]. A drop of the NP sus-
pension was placed on a glass cover slide and dried under
vacuum for 12 h. The slides were subsequently mounted
onto metal stubs using double-sided adhesive tape and
vacuum-coated with a thin layer (100 to 150 Å) of gold.
Then, the NPs were examined by SEM at 15 or 20 kV.
Encapsulation efficiency
The encapsulation efficiency (E.E.) of the NPs was deter-
mined by the cold centrifugation separation of NPs from
the aqueous medium containing the non-associated
MMP-1, and was calculated as E.E. (%) = [(Total protein
amount − Free protein amount)/Total protein amount] ×
100%. Briefly, samples were centrifuged (20,000 × g atTable 1 Independent variables and their corresponding
variables of NP preparation for RCCD
Variables Levels
−1.682 −1 0 +1 +1.682
X1 (min) 2 4 7 10 12
X2 (krpm) 2 2.8 4 5.2 6
X3 0.1 0.18 0.3 0.42 0.5
RCCD, rotatable central composite design; X1, duration time of
homogenization; X2, agitation speed of homogenization; X3, volume ratio of
organic solvent phase to external aqueous phase.4 °C for 10 min), and free MMP-1 in the supernatant
was determined using the MMP-1 ELISA kit as per
manufacturer's protocol: 100 μL of MMP-1 standard
solution or MMP-1-containing samples were added into
the microtiter plate wells, and then, all unbound sites
were blocked to prevent false positive results. Second,
100 μL of biotinylated antibody was added to each well
to combine MMP-1; then, 100 μL of prepared streptavi-
din solution was added. Third, 100 μL of TMB one-step
substrate reagent was added to each well to develop
color; then, the stop solution was added to change the
color from blue to yellow. The intensity of the color in
proportion to the amount of MMP-1 is measured at
450 nm. The test procedure was performed for a total of
three times for each sample.
MMP-1 activity assay
To evaluate the influence of the NP preparation proced-
ure on the MMP-1 enzymatic activity, we measured the
activity of the encapsulated MMP-1 using Acetyl-Pro-
Leu-Gly-[2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OC2H5
as the thioester substrate. The release of free thiols in
the presence of excess 5,50-dithiobis(2-nitrobenzoic acid)
(DTNB) was continuously monitored with a Varian Cary
50 ultraviolet spectrophotometer (Varian Inc., Palo Alto
Inc., CA, USA) at 412 nm for 30 min at 37 °C. Briefly,
20 mg of dried MMP-1-loaded NPs were first suspended
in 1 mL assay buffer (50 mM HEPES, 10 mM calcium
chloride, pH 7.5) at 37 °C with a stirring speed of
100 rpm for 3 days. Then, 200 μL of the release medium
was withdrawn and centrifuged at 20,000 × g for 10 min
at 4 °C; the supernatant was analyzed for MMP-1 mass
by using a MMP-1 ELISA kit following the manu-
facturer's protocol. For comparison, non-encapsulated
MMP-1 at the same concentration was treated with the
same method and used as the 100% bioactivity bench-
mark. Second, the released MMP-1 in the sample and
the non-encapsulated MMP-1 were activated respectively
via incubation with APMA (1 mM) for 2 h at 37 °C.
The DTNB (1 mM) was then added and pre-incubated
at 37 °C for 3 min prior to the addition of thioester sub-
strate (100 μM final concentration). The total reaction
volume was 100 μL. One unit of MMP-1 activity was
defined as the amount of enzyme required to catalyze
substrate hydrolysis at a rate of 1 Abs/min.
In vitro release of MMP-1 from NPs
In vitro release profile of MMP-1 from the optimized
NPs was performed using dialysis membrane diffusion
method [16]. Briefly, 50 mg of dried NPs were re-dispersed
in 2 mL PBS (pH 7.4) and placed in a dialysis membrane
bag with a cutoff MW of 100,000 Dalton (Spectrum Lab.,
Rancho Dominguez, CA, USA). The release experiment
was initiated by placing the end-sealed dialysis bag into
Table 2 RCCD consisting of three experimental factors in coded and actual levels with experimental results
Formulation Coded independent variables Actual independent variables Dependent variables
X1 X2 X3 X1 X2 X3 EE (%) Mean size
1 1 1 1 10 5.2 0.42 36.96 381.2
2 1 1 −1 10 5.2 0.18 28.12 321.1
3 1 −1 1 10 2.8 0.42 42.74 510.2
4 1 −1 −1 10 2.8 0.18 41.09 770.2
5 −1 1 1 4 5.2 0.42 49.08 426.3
6 −1 1 −1 4 5.2 0.18 44.67 371.9
7 −1 −1 1 4 2.8 0.42 61.98 806.7
8 −1 −1 −1 4 2.8 0.18 54.10 1,216.6
9 +1.682 0 0 12 4 0.3 20.14 420.6
10 −1.682 0 0 2 4 0.3 60.50 790.1
11 0 +1.682 0 7 4 0.3 32.38 362.7
12 0 −1.682 0 7 2 0.3 50.14 980.1
13 0 0 +1.682 7 4 0.5 47.22 522.2
14 0 0 −1.682 7 4 0.1 32.19 539.8
15 to 20 0 0 0 7 4 0.3 37.38 471.1
n= 3. EE, entrapment efficiency; RCCD, rotatable central composite design; X1, duration time of homogenization; X2, agitation speed of homogenization; X3,
volume ratio of organic solvent phase to external aqueous phase.
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100 rpm. At chosen time points, 1 mL release medium was
withdrawn and replaced with an equal volume of fresh
medium. The amount of the released MMP-1 mass was
measured by the MMP-1 ELISA kit [17]. Results were
expressed as cumulative release of MMP-1 from NPs with
three replicates.
Data analysis
For analyzing the influence of multiple factors, mathemat-
ical polynomial equation models of design were established
to correlate the independent variables to the dependent
variables. The obtained polynomial equation for each re-
sponse property was analyzed using RSM separately. By
solving the regression equation and also by analyzing the
response surface contour and surface plots, the optimal
levels of the selected independent variables were achieved.
Statistical tests were performed with STATISTICA 6.0 soft-
ware (analysis of variance (ANOVA)) to determine the stat-
istical significance of each model.
Results and discussion
Optimization analysis
Preparation of the NPs is a complex procedure as it
involves several variables. Even slight changes may have
significant impact on the quality of the final products
[18,19]. In this study, RCCD and RSM were implemented
to optimize the preparation procedure of the NPs, which
made it possible to investigate a high number of independ-
ent variables at different levels with only a limited numberof experiments [20,21]. The chosen independent variables
listed in Table 1 from our pilot experiments were taken
into account. Table 2 shows the experimental results con-
cerning the two tested variables on mean particle size and
encapsulation efficiency. The dependent variables ranged
from 321.1 to 1,216.6 nm and from 20.14% to 61.98%, re-
spectively, indicating sensitivity toward the critical factors
studied. For analysis of the influence of multiple factors,
quadratic equations were formulated to reflect the relation-
ship between the theoretical response and the independent
variables. The statistical analysis of the results generated
the following mathematical polynomial equations:
Y1 ¼ 4; 205:801 211:451 X1  938:574 X2
 4; 210:624 X3 þ 4:972 X12 þ 47:589 X22
þ 1; 248:918 X32 þ 22:465 X1X2 þ 54:028X1 X3
þ 680:903 X2X3 R¼0:989;F¼23:763; P ¼ 0:001ð Þ
Y2 ¼ 126:860 6:972 X1  20:600 X2  63:934 X3
þ 0:251 X12 þ 1:802 X22 þ 141:326 X32
þ 0:124X1X2  0:625 X1X3
þ 3:229 X2X3 R ¼ 0:962; F ¼ 6:988; P ¼ 0:023ð Þ
where X1, X2 and X3 represent the duration time of
homogenization, agitation speed of homogenization and
volume ratio of organic solvent phase to external aqueous
phase, and Y1 and Y2 represent the particle size and the
entrapment efficiency. The regression coefficients (R) of




Figure 1 Response surface plots of mean particle size (Y1) and entrapment efficiency (Y2) versus three factors. X1 = duration of
homogenization (min), X2 = agitation speed (krpm), and X3 = volume ratio of organic solvent phase to external aqueous phase (V/V). (A, B, C)
The effect of duration of homogenization, agitation speed and volume ratio of organic solvent phase to external aqueous phase on the mean
particle size. (D, E, F) The effect of duration of homogenization, agitation speed and volume ratio of organic solvent phase on the (EE)%.
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independent variables and dependent variables. ANOVA
analysis demonstrated that the quadratic equation models
are highly statistically significant (P< 0.05).The obtained polynomial equations were further ana-
lyzed using RSM, and the three-dimensional surface
plots were generated to describe the mathematical mod-
els (Figure 1). Figure 1A,B,C displays the effect of
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ratio of organic solvent phase to external aqueous phase
on the mean particle size. It can be seen from Figure 1A
that an increase in the duration and intensity of
homogenization within limits can lead to a remarkable
decrease in the mean particle size, whereas excessive
homogenizations can indeed increase the mean particle(A)
(C)
(D)
Figure 2 Optimum zone for NP preparation. (A) Overlapped contour pl
(B) overlapped contour plot for duration of homogenization (min) and volu
overlapped contour plot for agitation speed (krpm) and volume ratio of or
size distributions of MMP-1-loaded NPs (Gaussian distribution); (E) scanningsize again. The reason may be that excess dispersion can
lead to increase in viscosity of the emulsion solution
where high viscosity of the emulsion solution slows
down the dispersion of organic phase into aqueous
phase and leads to the formation of bigger aggregates.
Figure 1B shows that increasing the duration of the
homogenization and volume ratio of organic solvent(B)
(E)
ot for duration of homogenization (min) and agitation speed (krpm);
me ratio of organic solvent phase to external aqueous phase (V/V); (C)
ganic solvent phase to external aqueous phase (V/V); (D) DLS particle
electron microscopic images of MMP-1-loaded NPs.
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cles with smaller size. Figure 1C indicates that optimal
particle size can be achieved by taking suitable homo-
genization speed and volume ratio of organic solvent
phase to external aqueous phase.
Figure 1D,E,F indicates the effect of duration of
homogenization, agitation speed and volume ratio of
organic solvent phase to external aqueous phase on
entrapment efficiency. Figure 1D shows that an increase
in either duration of homogenization or agitation speed
all results in proportionate decrease in the entrapment
efficiency. Figure 1E,F shows that the increase in volume
ratio of organic solvent phase to external aqueous phase
can increase the entrapment efficiency, which may be
due to the fact that the organic solvent phase acts as a
disperse medium. However, when excess organic solvent
easily led to phase inversion, we observed that no NPs
could be achieved as soon as the amount of organic
solvent increased beyond limit in the experiments.
In addition, the optimum zone for NP preparation can
be readily found from Figure 2A (overlay of Figure 1A,
D), Figure 2B (overlay of Figure 1B,E) and Figure 2C
(overlay of Figure 1C,F). The optimized NPs with high
entrapment efficiency and small mean diameter were
obtained at the duration of homogenization of 7 min,
agitation speed of 4.5 krpm and volume ratio of organic
solvent phase of 0.4, respectively.
Under the suggested optimal preparation conditions,
309.49 nm of mean particle size and 39.15% of entrapment
efficiency were expected to be obtained according to the
above equation Y1 and Y2. The accuracy of the predicted
models was further examined by additional independent
experiments at the suggested optimal preparationFigure 3 In vitro kinetic curve for free and encapsulated MMP-1-catalconditions where the yielded NPs had an actual mean
particle size and entrapment efficiency of
322.7 ± 18.1 nm and 38.75± 4.74% (n= 3). The bias
values between the actual and predicted values were
4.4% and 1.0%, respectively, which was calculated as
(predicted-observed value)/predicted value × 100%. Thus,
these demonstrate that by utilizing the mathematical
models, optimal NPs can be obtained through a reliable
and reasonable manner.
Nanoparticle size and morphology
The mean diameter and particle size distributions of
the optimized NPs were determined by DLS measure-
ment [22]. The optimized NPs had a mean particle
size of 322.7 ± 18.1 nm and a polydispersity index below
0.3, indicating a relatively narrow size distribution
(Figure 2D).
The SEM image (Figure 2E) shows smooth, homoge-
neous and spherical-shaped spheres in nano range, and
there is no aggregation after lyophillization under the
optimal conditions. The NPs have an average particle
size of about 300 nm in the range of 100 to 400 nm,
which was similar to the data of DLS measurement.
In vitro activity of encapsulated MMP-1
MMP-1, like all MMPs, is expressed as a zymogen
(proMMP-1) and must, therefore, be activated by disrupt-
ing the interaction between a cysteine molecule in the enzy-
me's propeptide domain and a zinc molecule situated in the
active site. Latent MMP-1 can be activated in vitro by incu-
bation with organomercurial compounds and other chem-
ical agents that modify sulfhydryl groups. In vivo, MMP
activity is regulated by a group of endogenous proteins,yzed degradation of thioester peptide substrate. (n = 3).
Figure 4 In vitro release profile of the optimized MMP-1-loaded NPs. (n= 3).
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active and alternative sites of the activated MMP [23]. In
our study, the activity of the released MMP-1 in the super-
natant and free MMP-1 was measured by monitoring sub-
strate hydrolysis at 412 nm for 30 min at 37 °C. In the
initial phase (within the first 3 min), the kinetic curve
revealed a linear relationship, whereas the late phase
showed a slower and steady reaction progression (Figure 3).
We found minimal difference in terms of the enzymatic ac-
tivity between the encapsulated MMP-1 and free MMP-1
(0.03763±0.0012 vs. 0.03879±0.0008). Thus, our data
clearly demonstrated that the preparation procedure had
no obvious effect on the MMP-1 enzymatic activity.
In vitro release of optimal NPs
The NP formulation provided a sustained drug release pat-
tern, which was characterized by a burst release at the ini-
tial stage and a sustained release subsequently [24].
Figure 4 shows the cumulative in vitro release of MMP-1
from PLGA-PCL NPs where approximately one-third of
MMP-1 (36.13±0.39%) was released from the NPs within
the first 3 days (burst effect), and the rest (approximately
64%) was continuously but slowly released for the next
60 days. We believed that the initial burst effect was due to
the release of the surface-associated protein, whereas the
slower phase represented a continuous release of the
MMP-1 protein entrapped in the NPs. These results impli-
cate that the optimized NPs can be given as an ideal in vivo
MMP-1 prolonged release delivery system.
Conclusions
In the present study, we prepared MMP-1-loaded
PLGA-PCL NPs to provide controlled enzyme deliverysystem. We used RCCD and RSM to investigate the
impact of critical factors on the response properties and
optimize the conditions to lower the mean size of the
particles without jeopardizing its entrapment efficiency.
The optimized formulation provided a uniform small
particle size with high entrapment efficiencies. Moreover,
we characterized the optimized MMP-1-containing
PLGA-PCL NPs by DLS and SEM. In vitro drug release
study showed that the entrapped MMP-1 was released
over a period of 60 days in a controlled manner with
normal enzymatic activity. Taken together, these NPs are
therefore a promising system for prolonged release of
enzymes and have great potential application in better
control of MMP-1 therapy.
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